Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Lemoyneon Mar 26, 2021 7:53pm
185 Views
Post# 32891632

RE:RE:RE:Official website of new LABS brand

RE:RE:RE:Official website of new LABS brandClearly, they are focused on pharma, they are the only decent option for pharma white labelling, which is a beast sector, potential wise. But they also consider other sectors. Recreational white labeling doesn't seem to work out for them, at least not in canada. They have not managed to sign new white labels in canada and margins are probably not as good with price compression....To top it off, nothing guarantees current white labels will extend their contracts. They are clearly turning towards building their own brands, which bring in bigger margins. They are ahead of the curve vs VLNS on this one, even NEPT is going for private brands development.

Northbound clearly is value brand with 1G carts selling for 50$. Go for volume to burn through current inventory. If it manages to grow decently over the next quarters, it might manage to get rid of all the old inventory by mid 2021 with 1 or 2 write downs.

Then it would be set with solid balance sheet for 2021 2H, and shareholders might finally see the light.

I'm still sceptical about how investors will react to Q4 and Q1 even with increased revenues... They have really busted shareholders with the massive dilution and current revenue levels are just too low...

There was no update considering Q4 intl sales, for all we know, they could be flat or decreasing before we see Q1 increase with germany. I suspect bulk sales will be dismal/ not relevant. That leaves the 500k units, for which forum estimates are all over the place.
<< Previous
Bullboard Posts
Next >>